TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any veteran referred to the St. Louis VA Healthcare System stress testing laboratory for a cardiac stress test~Exclusion Criteria:~* Contra-indications to stress testing such as acute coronary syndrome, uncompensated heart failure, or unstable cardiac dysrhythmias Inability to perform arm exercise stress testing~* Contra-indications to regadenoson stress testing such as significant reversible airway disease, heart block, or low blood pressure~* An abnormal baseline ECG (e.g. left bundle branch block, widespread ST segment depression of at least 1 mm, ventricular paced rhythm) that precludes interpretation of the stress ECG~* Contra-indications to cardiac computed tomographic angiography (CTA) such as contrast allergies and renal dysfunction (glomerular filtration rate \< 30 ml/min)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- St. Louis VA Healthcare System stress testing referrals (Type: None): St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Dry Needling of the Sternocleidomastoid in Patients With Cervicogenic Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18-65 years old~2. Primary complaint of cervicogenic headache~3. Restricted cervical Range of motion~4. Neck Disability Index \> 20 points~Exclusion Criteria:~1. Red flags identified during the patients physical therapy initial evaluation (i.e. tumor, fracture, metabolic diseases, RA, osteoporosis, prolonged history of steroid use, symptoms of vertebrobasilary insufficiency, pregnancy, cervical spinal stenosis, bilateral upper extremity symptoms etc.~2. Use of blood thinners~3. History of whiplash injury within the past six weeks~4. Evidence of central nervous system involvement, to include hyperreflexia, sensory disturbances in the hand, intrinsic muscle wasting of the hands, unsteadiness during walking, nystagmus, loss of visual acuity, impaired sensation of the face, altered taste, the presence of pathological reflexes (i.e. positive Hoffman's and/or Babinski reflexes), etc.~5. Two or more positive neurologic signs consistent with nerve root compression, including any two of the following:~   1. Muscle weakness involving a major muscle group of the upper extremity~  2. Diminished upper extremity muscle stretch reflex (biceps brachii, brachioradialis, or triceps)~  3. Diminished or absent sensation to pinprick in any upper extremity dermatome~6. Prior surgery to the neck or thoracic spine~7. Chiropractic, Physical Therapy, or Acupuncture treatment for their neck pain in the last 6-months~8. Workers compensation or pending legal action regarding their headaches~9. Insufficient English language skills to complete all questionnaires~10. Inability to comply with treatment and follow-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- standard care group (Type: NO_INTERVENTION): Normal manual therapy interventions Clinician will decide normal course of treatment
- Dry needling (Type: EXPERIMENTAL): Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone CCP testing and patients who have not undergone CCP testing will be considered for enrollment in the study.~  1. Willing to provide written informed consent.~ 2. Males ≥65 years old.~ 3. Newly diagnosed (≤6 months), treatment-naïve patient with histologically proven localized adenocarcinoma of prostate whose initial treatment has not been decided.~ 4. Candidate for and considering AS and yet would be eligible for definitive therapy.~ 5. Favorable intermediate-risk disease, defined by the NCCN as follows:~     * predominant Gleason grade 3; AND~    * percentage of positive cores \<50%; AND~    * no more than 1 of the following NCCN intermediate-risk factors:~       * Gleason grade 7~      * T2b-T2c~      * PSA 10-20 ng/mL~ 6. Estimated life expectancy ≥10 years.~ 7. Can be monitored for disease progression according to standard of care (e.g., current NCCN guidelines).~Exclusion Criteria:~* 1. Clinical evidence of metastasis or lymph node involvement.~* 2. Received pelvic radiation prior to biopsy.~* 3. Received androgen deprivation therapy (ADT) prior to biopsy; however, 5 alpha-reductase inhibitors (5-ARIs) are permitted.~* 4. Participation in interventional clinical trials.~* 5. Patient is considering watchful waiting.~* 6. Has a known history of hypogonadism.

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prolaris Testing (Type: None): Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
- No Prolaris Testing (Type: None): Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Different Risk Assessment Strategies in Normotensive Pulmonary Embolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Pulmonary Embolism with hemodynamic stability (that is, SBP 90 mm Hg or more)~Exclusion Criteria:~Refuse of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ulipristal Acetate in Symptomatic Uterine Fibroid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-48~* Regular cycle of 22-35 days interval and FSH \<=20 mUI/mL.~* \>=1 uterine fibroid of 3\<= d \< 10cm (regardless of location), diagnosed by transvaginal ultrasound.~* Heavy menstrual bleeding (blood loss \>80ml/cycle).~* Uterine size \< 16 weeks of GA on clinical examination.~* Agree to participate in the study.~Exclusion Criteria:~* Previous or current treatment of uterus, cervix, ovarian or breast cancer.~* Previous endometrial ablation or uterine artery embolization.~* Abnormal PAP's smear result within 12 months prior to recruitment.~* Endometrial hyperplasia within 6 months prior to recruitment.~* Uterine polyp \>2cm.~* Ovarian cysts 4cm diagnosed by transvaginal ultrasound.~* Severe anemia (Hb 6 g/dl) or indication for blood transfusion.~* Coagulation disorder indicated for treatment.~* Increased liver enzyme level of twofold or more than normal upper limit.~* Previous use of SPRM.~* Treatment of systemic progestin or intrauterine device or hormonal contraception within 2 months, or use of GnRH analogue within 5 months prior to recruitment.~* Current use of acetylsalicylic acid, mefenamic acid, anticoagulation agents, antifibrinolysis agents, or systemic corticoid

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Ullipristal Acetate (Type: EXPERIMENTAL): Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are between 18 and 70 years of age at the time of signing the informed consent.~* Have a diagnosis of asthma according to the Guidelines for the Diagnosis and Management of Asthma and have not been treated with ICS in the previous two months.~* Have a PC20 methacholine less than 8 mg/ml.~* Have a baseline FEV1 greater or equal to 65% of predicted value (at least 6 hours after bronchodilator).~* Are not optimally controlled with short-acting 2 agonists as shown by awakenings due to asthmatic symptoms at least once a week, or regular use of salbutamol on 4 or more occasions per week (excluding exercise prophylaxis) due to asthma symptoms.~* ACQ score equal or greater than 2~* Have sputum eosinophils less than 2%~* Are non smokers or ex-smokers who smoked a maximum of 10 pack/year.~Exclusion Criteria:~* Hospitalized patients within the last 3 months~* Current or recent (within the last month) symptoms of a cold or flu~* Patients with a history of near fatal asthma~* Subjects on inhaled corticosteroids, prednisone, long-acting beta 2 agonists, montelukast or theophylline, within 2 months prior to entry into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment group (A) (Type: ACTIVE_COMPARATOR): Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
- Control group treated with placebo (B) (Type: PLACEBO_COMPARATOR): treatment with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Doxycycline in Relapsed NHL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed aggressive or indolent NHL following any prior treatment of the following etiologies:~  * Diffuse large B cell lymphoma (DLBCL)~ * Mantle cell lymphoma (MCL)~ * Follicular lymphoma (FL)~ * Marginal zone lymphoma (MZL)~ * Lymphoplasmacytic lymphoma (LPL)~ * Waldenstrom's macroglobulinemia (WM)~ * Small lymphocytic lymphoma (SLL)~ * Chronic lymphocytic leukemia (CLL)~ * T cell lymphoma (TCL)~* Ages ≥ 18~* Karnofsky Performance Status (KPS) ≥ 60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤2~* Life expectancy of at least 3 months~* Measurable disease in at least one target lesion, assessable by radiographic examination with Fludeoxyglucose-Positron Emission Tomography (FDG-PET) or computed tomography (CT), bone marrow evaluation showing involvement, or peripheral blood showing involvement of lymphoma~* Adequate organ function:~  * Absolute neutrophil count (ANC) \> 500 cells/mL and platelet count \> 50,000 cells/mL unless felt to be secondary to lymphoma at which any count is permissible.~ * Adequate renal function as determined by Creatinine (Cr) \< 1.5x upper limit of normal (ULN) or estimated creatinine clearance of ≥ 60mL/min~ * Adequate hepatic function as determined by total bilirubin \< 1.5x upper limit of normal (ULN) (unless known Gilbert syndrome), alanine aminotransferase (ALT)and aspartate aminotransferase (AST) \< 2.5x upper limit of normal (ULN)~Exclusion Criteria:~* Known sensitivity or allergy to tetracyclines~* Lack of measurable disease by computed tomography (CT) or Fludeoxyglucose-Positron Emission Tomography (FDG-PET)~* Karnofsky Performance Status (KPS) \<60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) \>2~* Curative treatment is indicated or possible~* Inadequate organ function as measured by not fulfilling above criteria~* Pregnancy, positive serum human chorionic gonadotropin (hCG) within 28 days of enrollment, or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Doxycycline 200 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Clinical diagnosis of non-radicular moderate-to-severe CLBP for ≥3 months (prior to screening visit)~2. Clinical diagnosis of OA in at least 1 hip or knee joint based on the American College of Rheumatology Criteria with radiographic evidence of OA (K-L ≥2) at screening~3. History of inadequate relief of CLBP from non-pharmacologic therapy~4. Willing to undergo joint replacement (JR) surgery, if necessary~5. History of regular analgesic medication use~6. History of inadequate pain relief or intolerance to analgesics used for chronic LBP~Key Exclusion Criteria:~1. Patient is not a candidate for MRI~2. History of major trauma or back surgery in the past 6 months prior to the screening visit~3. History or presence of pyriformis syndrome~4. Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions~5. History or evidence on joint imaging of conditions that may confound joint safety evaluation~6. Evidence or symptoms consistent with autonomic dysfunction (e.g., orthostatic hypotension and/or autonomic symptoms) as defined in the protocol~7. Recent use of longer acting pain medications~8. Other medical conditions that may interfere with participation or accurate assessments during the trial~Note: Other protocol defined Inclusion/ Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fasinumab (Type: EXPERIMENTAL): Subcutaneous (SC) every 4 weeks (Q4W)
- Placebo (Type: EXPERIMENTAL): SC every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LGX818 for Patients With BRAFV600 Mutated Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of melanoma and colorectal cancer (CRC)) or hematologic malignancies and is in need of treatment because of progression or relapse.~* Patient's tumor has been evaluated and pre-identified as having a tumor with a BRAFV600 mutation at a CLIA certified laboratory.~* Patient must have received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.~* Patient must have progressive and measurable disease per RECIST 1.1. or other appropriate hematological response criteria.~* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~Exclusion Criteria:~* Patient has received prior treatment with LGX818.~* Patients with Central Nerve System (CNS) metastasis or leptomeningeal carcinomatosis.~* Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug.~* Patients with acute or chronic pancreatitis.~* Patients with impaired cardiac function or clinically significant cardiac diseases.~* Patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LGX818 (Type: EXPERIMENTAL): LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Kaposi's sarcoma (KS) involving the following:~  * Skin~ * Lymph nodes (palpable disease only)~ * Oral cavity~* Must have ≥ 5 measurable, previously nonirradiated, cutaneous lesions that can be used as indicator lesions~* Must have 2 lesions ≥ 5 x 5 mm that are accessible for 4 mm punch biopsy~* Serologically confirmed HIV positivity~* Concurrent antiretroviral therapy required, except for patients who have exhausted all available treatment options~  * Must be on a stable dose for ≥ 4 weeks~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 3 months~* No other neoplasia requiring cytotoxic therapy~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior anthracycline therapy~* At least 4 weeks since prior antineoplastic treatment for KS, including any of the following:~  * Chemotherapy (6 weeks for nitrosoureas or mitomycin C)~ * Radiotherapy~ * Local therapy~ * Biological therapy~ * Investigational therapy~* At least 60 days since prior local therapy of any KS indicator lesion unless lesion has clearly progressed since treatment~* No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liposomal daunorubicin citrate (Type: EXPERIMENTAL): 40 mg/m2 Days 1 and 15 every 28 days x 3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men from 18 to 65 years old~* Women from 18 years old to menopause~* Patient with a polyarthritis rheumatoid no controlled by the usual treatment (DAS28\>3)~* Patient affiliated or beneficiary of a national insurance system~* Patient with signed consent~Exclusion Criteria:~* Concomitant osseous disease (Paget's disease, osteomalacia...)~* Endocrinopathy defined on biological criteria (Cushing's disease, hyperthyroidism, hypogonadism...)~* Patients under protection of justice~* Refusal consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- patients with anti-TNF therapy (Type: OTHER): patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues